uniQure N.V. to Report Q4 and Full Year 2025 Financial Results on March 2, 2026

uniQure will announce its 2025 financial results on March 2, 2026, followed by a conference call.

Quiver AI Summary

uniQure N.V., a gene therapy company, will release its financial results for the fourth quarter and full year of 2025 on March 2, 2026, prior to market opening. Following the release, management will hold a conference call at 8:00 a.m. ET, which will be available via webcast on the company's website. Analysts can participate in the Q&A by calling in and using a provided conference ID. uniQure is known for its gene therapy treatment for hemophilia B, marking a significant advancement in gene therapy, and is developing additional therapies for various severe conditions, including Huntington's disease and ALS.

Potential Positives

uniQure will report its financial results for the fourth quarter and full year of 2025, providing transparency and accountability to investors.
The upcoming conference call will allow analysts and investors to engage directly with management, facilitating open communication and feedback.
uniQure's gene therapy for hemophilia B is highlighted as a historic achievement, reinforcing the company’s leadership in the gene therapy field.
The advancement of a diverse pipeline of proprietary gene therapies for severe diseases positions uniQure for potential growth and innovation in the industry.

Potential Negatives

Announcement of the financial results may raise concerns if analysts predict poor performance or significant losses.
Potential overreliance on a limited number of therapies for severe diseases, which may create risks if these therapies do not succeed in the market.
Failure to provide details on the financial performance could lead to uncertainty among investors regarding the company's financial health.

FAQ

When will uniQure report its Q4 and full year 2025 financial results?

uniQure will report its financial results on March 2, 2026, before the market opens.

What time is the uniQure conference call scheduled?

The conference call is scheduled for 8:00 a.m. ET on March 2, 2026.

How can I access the uniQure conference call?

You can access the call by dialing (646) 307-1963 or toll-free (800) 715-9871 with conference ID 4607289.

Where can I find the webcast of the event?

The webcast will be available in the Events & Presentations section of uniQure’s website.

What diseases are included in uniQure's pipeline of gene therapies?

uniQure's pipeline includes therapies for Huntington's disease, ALS, Fabry disease, and more.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$QURE Insider Trading Activity

$QURE insiders have traded $QURE stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:

MATTHEW C KAPUSTA (CEO, Managing Director) has made 0 purchases and 5 sales selling 226,316 shares for an estimated $9,382,472.
ROBERT GUT has made 0 purchases and 5 sales selling 57,047 shares for an estimated $1,487,364.
JACK KAYE has made 0 purchases and 4 sales selling 45,200 shares for an estimated $1,351,836.
CHRISTIAN KLEMT (Chief Financial Officer) has made 0 purchases and 2 sales selling 18,000 shares for an estimated $945,120.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$QURE Hedge Fund Activity

We have seen 137 institutional investors add shares of $QURE stock to their portfolio, and 137 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ECOR1 CAPITAL, LLC removed 3,988,971 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $95,456,076
STATE STREET CORP added 1,787,033 shares (+123.8%) to their portfolio in Q4 2025, for an estimated $42,763,699
JPMORGAN CHASE & CO added 1,785,275 shares (+155.3%) to their portfolio in Q4 2025, for an estimated $42,721,630
AVORO CAPITAL ADVISORS LLC added 1,705,556 shares (+38.4%) to their portfolio in Q4 2025, for an estimated $40,813,955
RTW INVESTMENTS, LP removed 1,446,769 shares (-28.0%) from their portfolio in Q4 2025, for an estimated $34,621,182
MPM BIOIMPACT LLC added 1,381,628 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,062,358
FRANKLIN RESOURCES INC removed 1,241,979 shares (-62.5%) from their portfolio in Q4 2025, for an estimated $29,720,557

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$QURE Analyst Ratings

Wall Street analysts have issued reports on $QURE in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stifel issued a "Buy" rating on 12/11/2025
Mizuho issued a "Outperform" rating on 12/09/2025
Wells Fargo issued a "Overweight" rating on 11/12/2025
Leerink Partners issued a "Outperform" rating on 11/10/2025
HC Wainwright & Co. issued a "Buy" rating on 11/04/2025
RBC Capital issued a "Outperform" rating on 11/04/2025
Chardan Capital issued a "Buy" rating on 11/03/2025

To track analyst ratings and price targets for $QURE, check out Quiver Quantitative's $QURE forecast page.

$QURE Price Targets

Multiple analysts have issued price targets for $QURE recently. We have seen 11 analysts offer price targets for $QURE in the last 6 months, with a median target of $53.0.

Here are some recent targets:

Patrick R. Trucchio from HC Wainwright & Co. set a target price of $70.0 on 02/10/2026
Eliana Merle from Barclays set a target price of $31.0 on 01/28/2026
Paul Matteis from Stifel set a target price of $40.0 on 12/11/2025
Uy Ear from Mizuho set a target price of $33.0 on 12/09/2025
Daniil Gataulin from Chardan Capital set a target price of $53.0 on 12/04/2025
Yanan Zhu from Wells Fargo set a target price of $60.0 on 11/12/2025
Joseph Schwartz from Leerink Partners set a target price of $60.0 on 11/10/2025

Full Release

LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations , and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 4607289. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:	FOR MEDIA:

Chiara Russo	Tom Malone
Direct: 781-491-4371	Direct: 339-970-7558
Mobile: 617-306-9137	Mobile:339-223-8541
[email protected]	[email protected]